USA flag logo/image

An Official Website of the United States Government

DETECTION OF ALZHEIMER'S DISEASE USING A POLYMER NANOWIRE-BASED BIOSENSOR

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
88661
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
AG029006
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Innosense, LLC
2531 West 237th Street Torrace, CA 90505-5245
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: DETECTION OF ALZHEIMER'S DISEASE USING A POLYMER NANOWIRE-BASED BIOSENSOR
Agency: HHS
Contract: 1R43AG029006-01A1
Award Amount: $367,279.00
 

Abstract:

DESCRIPTION (provided by applicant): InnoSense LLC (ISL) submits this revised application with the intent of developing a cost-effective and highly sensitive polymer nanowire-based electronic biosensor (PNEBD) for the early screening of Alzheimer's disease (AD). This device is expected to have potentially significant implications in the early treatment and possible delay of debilitating symptoms associated with this disease. The Phase I project is focused on the development and verification of a high-throug hput device based on silicon photolithography processes and template-free electrodeposition of functionalized conductive polymers between narrow-gap electrode junctions. Six tasks have been proposed to establish the Phase I feasibility of detecting amyloid -a derived diffusible ligand (ADDL) antigen, a biomarker for AD, using amyloid-a (Aa) oligomer specific antibody to ADDLs. Current evidence strongly suggests a central role for amyloid-a (Aa) in the pathogenesis of AD. At the present time there is no defin ite clinical diagnosis for AD other than autopsy. It has been demonstrated that ADDLs are present at significantly elevated levels in the autopsied brain samples of humans with AD. This association of ADDLs with AD suggests that the PNEBD device could prov ide a definitive molecular basis for the laboratory diagnosis of AD. For ensuring success, a highly skilled research team, including an expert on AD, has been assembled to execute the project. Development of ultrasensitive detection methods for early scree ning of Alzheimer's disease (AD) is an important issue in clinical disease diagnosis and mechanistic understanding of Alzheimer's disease (AD). AD is a progressive neurodegenerative disease for which there is neither a cure nor an early diagnostic device. It is the leading cause of dementia in people over age 65 affecting over four million Americans. Despite its utmost importance, no ultrasensitive technologies have been developed for clinical lab diagnostic of AD. InnoSense LLC aims to fill this void by de veloping a cost-effective and highly-sensitive polymer nanowire-based electronic biosensor device (PNEBD). This device will utilize electrochemically grown polymer nanowires at micro- to nanoscale patterned electrode junctions for detecting amyloid-a deriv ed diffusible ligands (ADDLs). ADDL has been established as a biomarker for AD. The purpose of using an electrochemical method is to grow template-free, low-cost and high quality polymer nanowires on to the electrode junctions. This direct, one-step fabric ation technique is scalable. This project will advance our knowledge on the detection of Alzheimer's disease.

Principal Investigator:

Business Contact:


kisholoy.goswami@innosense.us
Small Business Information at Submission:

INNOSENSE, LLC
INNOSENSE, LLC 2531 W 237TH ST, STE 127 TORRANCE, CA 90505

EIN/Tax ID: 364501803
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No